In the FeDeriCa trial, with the neoadjuvant, the fixed-dose combination of pertuzumab and trastuzumab by subcutaneous injection provided similar total pathological complete response rates to intravenous injection of pertuzumab plus trastuzumab in patients with early stage HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.